The 'DOSE' refers to a cannabinoid profile. Our flower labels list cannabinoids as % per gram.
“THC had a moderate and lengthy effect [on pain].”
“Nevertheless, the impression gained from these studies was that certain doses of THC, particularly with repeated ingestion, may reduce rapid eye movement (REM) activity and increase slow-wave sleep.”
“THC was found to significantly decrease the time it takes to fall asleep in physically healthy insomniacs.”
“Results of this study show that Delta(9)-THC and other cannabinoids exert antidepressant-like actions, and thus may contribute to the overall mood-elevating properties of cannabis.”
“THC tended to be associated with some decrease in awakenings in the first half of the night.”
“Conversely, cannabidiol significantly reduced total chow consumption over the test period.”
“Accordingly, CBD has been shown to reduce amygdalar responses to fearful stimuli ; this mechanism may be essential for the anxiolytic effects of this compound in social phobia . Furthermore, CBD has been shown to elicit antipanic effects through the activation of 5-HT1A receptors in the dorsal periaqueductal gray, a critical area for the modulation of emotional reactivity to stress [208,209].”
“CBD… stimulated descending pathways of antinociception and caused analgesia by interacting with several target proteins involved in nociceptive control. [CBD] might represent useful therapeutic agents with multiple mechanisms of action.”
“Subjects receiving 160 mg cannabidiol reported having slept significantly more than those receiving placebo; the volunteers also reported significantly less dream recall; with the three doses of cannabidiol than with placebo.”
“The consumption of 2.5mg to 5mg of CBN has the same level of sedation as a mild pharmaceutical sedative, with a relaxed body sensation similar to 5mg to 10mg of diazepam. CBN is synergistic with both CBD and D9THC for inducement of sleeping, and when mixed in the correct ratios, CBN becomes an effective sleep aid of 5-6 hours duration.”
“This is the first time cannabinol has been shown to increase feeding. Therefore, cannabinol could, in the future, provide an alternative to the currently used and psychotropic ∆(9)-tetrahydrocannabinol-based medicines since cannabinol is currently considered to be non-psychotropic. Furthermore, cannabidiol reduced food intake in line with some existing reports, supporting the need for further mechanistic and behavioral work examining possible anti-obesity effects of cannabidiol.”
”This investigation has provided the first evidence that cannabigerol can activate α2-adrenoceptors, bind to cannabinoid CB1 and CB2 receptors and block CB1 and 5-HT1A receptors.” [C]annabigerol can indeed inhibit noradrenaline reuptake, this would be consistent with a preliminary report that it increases struggling behaviour in the mouse tail suspension test, an indication that it may possess antidepressant activity.
“CBC had a weak analgetic action in mice”
“CBC stimulated descending pathways of antinociception and caused analgesia by interacting with several target proteins involved in nociceptive control. [CBC] might represent useful therapeutic agents with multiple mechanisms of action.”
Cannabinoid receptors have also been found in fat and the liver, which might explain why GW Pharma’s compound THCV improved metabolic abnormalities associated with cardiovascular disease and diabetes in animals.
“Additionally, the propylated form of THC (THCV), induced weight loss, decreased body fat and serum leptin concentrations with increased energy expenditure in a murine study . is particular study poses interest in creating molecules similar to THCV as potential dietary drugs.”